Cognition Therapeutics Q4 EPS $(0.27) Beats $(0.34) Estimate
Portfolio Pulse from Happy Mohamed
Cognition Therapeutics (NASDAQ:CGTX) reported Q4 losses of $(0.27) per share, surpassing the analyst consensus estimate of $(0.34) by 20.59%. However, this represents a 35% increase in losses compared to $(0.20) per share from the same period last year.
March 26, 2024 | 1:28 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cognition Therapeutics reported better-than-expected Q4 losses but with an increase in losses year-over-year.
While beating the EPS estimate is positive, the increase in losses year-over-year could concern investors. The mixed results make the short-term impact on the stock price uncertain, hence a neutral score.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100